In CRC with KRAS G12D, 462 (23.3%) had TMB ≥ 35, 406 (20.5%) had TMB ≥ 50, 311 (15.7%) had TMB ≥ 75, and 241 (12.2%) had TMB ≥ 100. This evidence concerns the gene KRAS and colorectal carcinoma.